| Chronic myeloid leukemia: second‐line drugs of choice C Gambacorti‐Passerini, A Aroldi, N Cordani, R Piazza American journal of hematology 91 (1), 67-75, 2016 | 40 | 2016 |
| Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy E Bossi, A Aroldi, FA Brioschi, C Steidl, S Baretta, R Renso, L Verga, ... American journal of hematology 95 (12), E319-E321, 2020 | 31 | 2020 |
| Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis EM Elli, A Belotti, A Aroldi, M Parma, P Pioltelli, EM Pogliani Mediterranean Journal of Hematology and Infectious Diseases 6 (1), 2014 | 21 | 2014 |
| Tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: eligibility criteria and predictors of success E Inzoli, A Aroldi, R Piazza, C Gambacorti‐Passerini American Journal of Hematology 97 (8), 1075-1085, 2022 | 18 | 2022 |
| Treatment of Philadelphia‐negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors A Andriani, E Elli, G Trapè, N Villivà, L Fianchi, A Di Veroli, P Niscola, ... Hematological oncology 37 (3), 291-295, 2019 | 17 | 2019 |
| Integrated genomic, functional, and prognostic characterization of atypical chronic myeloid leukemia D Fontana, D Ramazzotti, A Aroldi, S Redaelli, V Magistroni, A Pirola, ... Hemasphere 4 (6), e497, 2020 | 15 | 2020 |
| ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK. CAR-T cells E Bergaggio, WT Tai, A Aroldi, C Mecca, E Landoni, M Nüesch, I Mota, ... Cancer cell 41 (12), 2100-2116. e10, 2023 | 12 | 2023 |
| CD24/Siglec-10 “Don't Eat Me” signal blockade is a potential immunotherapeutic target in mantle-cell lymphoma A Aroldi, M Mauri, M Parma, E Terruzzi, M Fedele, P Perfetti, F Cocito, ... Blood 138, 2276, 2021 | 12 | 2021 |
| Neurological symptoms in essential thrombocythemia: impact of JAK 2 V 617 F mutation and response to therapy A Aroldi, C Cecchetti, A Colombo, L Cattaneo, PE Pioltelli, EM Pogliani, ... European Journal of Haematology 96 (6), 593-601, 2016 | 12 | 2016 |
| Advances and hurdles in CAR T cell immune therapy for solid tumors F Boccalatte, R Mina, A Aroldi, S Leone, CM Suryadevara, ... Cancers 14 (20), 5108, 2022 | 10 | 2022 |
| Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study) EM Elli, A Iurlo, A Aroldi, M Caramella, S Malato, E Casartelli, M Maffioli, ... British journal of haematology 186 (5), e123-e126, 2019 | 10 | 2019 |
| Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea R Renso, A Aroldi, P Pioltelli, C Gambacorti-Passerini, EM Elli Blood cancer journal 8 (6), 56, 2018 | 10 | 2018 |
| Post-transplant lymphoproliferative disease (PTLD) after allogeneic hematopoietic stem cell transplantation: biology and treatment options M Clerico, I Dogliotti, A Aroldi, C Consoli, L Giaccone, B Bruno, F Cavallo Journal of Clinical Medicine 11 (24), 7542, 2022 | 9 | 2022 |
| A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas G Rindone, A Aroldi, E Bossi, L Verga, G Zambrotta, S Tarantino, ... Blood Advances 7 (3), 314-316, 2023 | 8 | 2023 |
| Effects of blocking CD24 and CD47 ‘don't eat me’signals in combination with rituximab in mantle‐cell lymphoma and chronic lymphocytic leukaemia A Aroldi, M Mauri, D Ramazzotti, M Villa, F Malighetti, V Crippa, F Cocito, ... Journal of Cellular and Molecular Medicine 27 (20), 3053-3064, 2023 | 7 | 2023 |
| Imatinib Suspension and Validation (ISAV) Study: results at 24 months S Mori, P le Coutre, E Abruzzese, B Martino, E Pungolino, C Elena, I Pierri, ... Blood 126 (23), 2775, 2015 | 6 | 2015 |
| Evaluating the performance of large language models in haematopoietic stem cell transplantation decision‐making I Civettini, A Zappaterra, BM Granelli, G Rindone, A Aroldi, S Bonfanti, ... British journal of haematology 204 (4), 1523-1528, 2024 | 5 | 2024 |
| Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients D Fontana, I Crespiatico, V Crippa, F Malighetti, M Villa, F Angaroni, ... Nature Communications 14 (1), 5982, 2023 | 4 | 2023 |
| Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies C Gambacorti-Passerini, M Ruggeri, A Aroldi, R Piazza, A Mazzi, ... Transfusion and Apheresis Science 60 (3), 103105, 2021 | 4 | 2021 |
| Characterization of SARS-CoV-2 mutational signatures from 1.5+ million raw sequencing samples A Aroldi, F Angaroni, D D’Aliberti, S Spinelli, I Crespiatico, V Crippa, ... Viruses 15 (1), 7, 2022 | 2 | 2022 |
